Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

PHASE3CompletedINTERVENTIONAL
Enrollment

549

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Non-Hodgkin LymphomasFollicular LymphomasImmunocytomasLymphocytic LymphomasMarginal Zone Lymphomas
Interventions
DRUG

Bendamustine

Comparison of Bendamustine + Rituximab with CHOP + Rituximab

DRUG

Standard chemotherapy CHOP + Ritiximab

Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy

Trial Locations (1)

35392

StiL Head Office; Justus-Liebig-University, Giessen

All Listed Sponsors
lead

University of Giessen

OTHER

NCT00991211 - Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | Biotech Hunter | Biotech Hunter